Patents by Inventor Steven Zeman

Steven Zeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody neutralizers of human granulocyte macrophage colony stimulating factor
    Patent number: 10138297
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 27, 2018
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Julia Hepp (nee Henckel), Eva Vieser (nee Krinner), Silke Petsch (nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
  • Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor
    Publication number: 20160130338
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 12, 2016
    Inventors: Tobias Raum, Julia Hepp (nee Henckel), Eva Vieser (nee Krinner), Silke Petsch (nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
  • Antibody neutralizers of human granulocyte macrophage colony stimulating factor
    Patent number: 9067993
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: June 30, 2015
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Julia Hepp, Eva Vieser, Silke Petsch, Steven Zeman, Andreas Wolf, Sandra Bruckmaier
  • Human-anti-human cd3 binding molecules
    Patent number: 8784821
    Abstract: The present invention provides a method for the preparation of a human binding molecule, fragment or derivative thereof which specifically binds to the human CD3 complex. Furthermore, the invention provides a human binding molecules specifically binding to the human CD3 complex and means comprising said human binding molecules.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: July 22, 2014
    Assignee: Amgen Research (Munich) GmbH
    Inventors: Peter Kufer, Tobias Raum, Meera Berry, Roman Kischel, Susanne Mangold, Eva Krinner, Birgit Kohleisen, Steven Zeman, Christian Itin, Patrick Bäuerle
  • ANTIBODY NEUTRALIZERS OF HUMAN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR
    Publication number: 20120009195
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Application
    Filed: August 4, 2011
    Publication date: January 12, 2012
    Applicant: MICROMET AG
    Inventors: TOBIAS RAUM, JULIA HEPP (NEE HENCKEL), EVA VIESER (NEE KRINNER, SILKE PETSCH (NEE MITTELSTRASS), STEVEN ZEMAN, ANDREAS WOLF, SANDRA BRUCKMAIER
  • Antibody neutralizers of human granulocyte macrophage colony stimulating factor
    Patent number: 8017748
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: September 13, 2011
    Assignee: Micromet AG
    Inventors: Tobias Raum, Julia Hepp (Nee Henckel), Eva Vieser (Nee Krinner), Silke Petsch (Nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
  • Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
    Patent number: 7635472
    Abstract: The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: December 22, 2009
    Assignee: Micromet AG
    Inventors: Peter Kufer, Ralf Lutterbuse, Birgit Kohleisen, Steven Zeman, Patrick Bauerle
  • Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor
    Publication number: 20090297532
    Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.
    Type: Application
    Filed: April 18, 2006
    Publication date: December 3, 2009
    Applicant: Micromet AG
    Inventors: Tobias Raum, Julla Hepp (Nee Henckel), Eva Krinner, Silke Petsch (Nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
  • Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
    Publication number: 20070123479
    Abstract: The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order, VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3), VH(CD3)-VL-(CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.
    Type: Application
    Filed: May 26, 2004
    Publication date: May 31, 2007
    Applicant: MICROMET AG
    Inventors: Peter Kufer, Ralf Lutterbuse, Birgit Kohleisen, Steven Zeman, Patrick Bauerle